<DOC>
	<DOCNO>NCT01634152</DOCNO>
	<brief_summary>The overall purpose trial evaluate efficacy safety tiotropium inhalation solution ( 2.5 mcg 5 mcg ) deliver via Respimat® inhaler daily even 12 week , compare placebo , add-on controller therapy top usual care child ( 6 11 year old ) severe persistent asthma .</brief_summary>
	<brief_title>Efficacy Safety 2 Doses Tiotropium Respimat® Compared Placebo Children With Severe Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Inclusion criterion : Inclusion criterion : 1 . All patient ' parent ( ) ( legal guardian ) must sign date inform consent prior participation trial . In addition , inform assent suitable age group obtain patient . A separate informed consent/assent require pharmacogenomic sampling . 2 . Male female patient 6 11 year age . 3 . All patient must least 6month history asthma . 4 . All patient must maintenance treatment inhale corticosteroid either stable high dose combination another controller medication , OR stable medium dose combination two controller medication , least 4 week Visit 1 . 5 . All patient must symptomatic ( partly control ) Visit 1 prior randomisation Visit 2 define Asthma Control Questionnaire ( ACQIA ) mean score &gt; = 1.5 . 6 . All patient must prebronchodilator forced expiratory volume one second ( FEV1 ) &gt; = 60 % &lt; = 90 % predict normal Visit 1 . 7 . Variation absolute FEV1 value Visit 1 ( prebronchodilator , consider 100 % ) compare Visit 2 ( predose ) must within ± 30 % . 8 . All patient must confirm diagnosis asthma bronchodilator reversibility Visit 1 , result increase FEV1 &gt; = 12 % 15 30 minute 200 mcg salbutamol/albuterol . 9 . Patients must able use Respimat inhaler correctly . 10 . Patients must able perform trial related procedure include technically acceptable pulmonary function test use electronic diary/peak flow meter ( diary compliance least 80 % require ) . Exclusion criterion : Exclusion criterion : 1 . Patients significant disease asthma . 2 . Patients clinically relevant abnormal haematology blood chemistry screen . 3 . Patients history congenital acquire heart disease , patient hospitalise cardiac syncope failure past year . 4 . Patients unstable lifethreatening cardiac arrhythmia cardiac arrhythmia require intervention change drug therapy within past year . 5 . Patients malignancy patient undergone resection , radiation therapy chemotherapy within last five year . 6 . Patients know active tuberculosis . 7 . Patients undergone thoracotomy pulmonary resection . 8 . Patients currently pulmonary rehabilitation program complete pulmonary rehabilitation program six week prior Visit 1 . 9 . Patients know hypersensitivity anticholinergic drug , BAC , EDTA components inhalation solution use Respimat inhaler . 10 . Pregnant nursing female patient , include postmenarchal girl positive urine pregnancy test Visit 1 . 11 . Postmenarchal girls childbearing potential use highly effective method birth control . 12 . Patients treat systemic corticosteroid within four week prior Visit 1 . 13 . Patients treat systemic betaadrenergics within four week prior Visit 1 . 14 . Patients treat oral betablocker medication within four week prior Visit 1 and/or screen period . 15 . Patients treat inhaled longacting anticholinergic systemic anticholinergic treatment within four week prior Visit 1 and/or screening period , treat inhaled shortacting anticholinergic within two week prior Visit 1 . 16 . Patients treat shortacting theophylline preparation within two week prior Visit 1 . 17 . Patients treat nonapproved accord international guideline recommend experimental drug routine asthma therapy within four week prior Visit 1 and/or screen period . 18 . Patients take investigational drug within six half life accord investigator 's information , four week ( whichever great ) prior Visit 1 and/or screen period . 19 . Patients previously randomise trial currently participate another trial . 20 . Patients acute asthma exacerbation respiratory tract infection four week prior Visit 1 and/or four week prior Visit 2 . In case asthma deterioration occur four week prior Visit 1 and/or four week prior Visit 2 , visit must postpone . 21 . Patients require six puff rescue medication per day two consecutive day four week prior Visit 1 and/or four week prior Visit 2 . In case asthma deterioration occur four week prior Visit 1 and/or four week prior Visit 2 , visit must postpone . 22 . Patients unable comply medication restriction prior Visit 1 and/or prior Visit 2 . 23 . Patients know narrowangle glaucoma , disease anticholinergic treatment contraindicate . 24 . Patients moderate severe renal impairment , define creatinine clearance &lt; 50 mL/min/1.73 m2 BSA , tiotropium predominantly renally excrete drug .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>